PART A

Sec. A-1. 22 MRSA §254, sub-§8-B is enacted to read:

8-B.__Action with regard to nonparticipating manufacturers and labelers.__The names of manufacturers and labelers who do and do not enter into rebate agreements pursuant to subsection 8 are public information.__The department shall release this information to health care providers and the public on a regular basis and shall publicize participation by manufacturers and labelers that is of particular benefit to the public.

Sec. A-2. 22 MRSA §2681, sub-§7, as enacted by PL 1999, c. 786, Pt. A, §3, is amended to read:

7. Action with regard to nonparticipating manufacturers and labelers. The names of manufacturers and labelers who do and do not enter into rebate agreements pursuant to this subchapter are public information. The department shall release this information to health care providers and the public on a regular basis and shall publicize participation by manufacturers and labelers that is of particular benefit to the public. The department shall impose prior authorization requirements in the Medicaid program under this Title, as permitted by law, for the dispensing of prescription drugs provided by those manufacturers and labelers.

PART B

Sec. B-1. Business Advisory Committee on Prescription Drug Costs and Efficiencies. The Business Advisory Committee on Prescription Drug Costs and Efficiencies, referred to in this section as the "committee," is established.

1. Membership. The committee consists of 12 members appointed as follows:

A. Two members of the Senate, one from each of the 2 political parties with the greatest number of elected members, appointed by the President of the Senate;

B. Two members of the House of Representatives, one from each of the 2 political parties with the greatest number of elected members, appointed by the Speaker of the House;

C. The Commissioner of Human Services or the commissioner's designee;